{"type":"trials","record":{"id":41429,"source_id":"clinicaltrials-gov","external_id":"NCT05210803","title":"Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD","brief_summary":"This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for up to 5 years after ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.","overall_status":"Enrolling By Invitation","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"AbbVie","enrollment":116,"countries":["United States"],"start_date":"2021-12-20","completion_date":"2031-07-01","last_update_date":"2026-08-05","source_url":"https://clinicaltrials.gov/study/NCT05210803","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":null,"comparator":null,"organization":"AbbVie","interventions":["Standard of Care","Ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidences of ocular Adverse Events and any Serious Adverse Events — 5 years inclusive of parent study","Incidences of non-ocular Adverse Events and any Adverse Events of Special Interest — 5 years inclusive of parent study","Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA based on ETDRS score i…","Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CRT as measured by SD-OCT i…","Mean number of supplemental anti-VEGF injections through years 2, 3, 4 and 5 — 5 years inclusive of parent study","Mean number of supplemental anti-VEGF injections in years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean supplemental anti-VEGF injection annualized rate through years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean supplemental anti-VEGF injection annualized rate in years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean number of retina specialist visits attended for nAMD through years 2, 3, 4, and 5 — 5 years inclusive of parent st…","Mean number of retina specialist visits attended for nAMD in years 2, 3, 4, and 5 — 5 years inclusive of parent study"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD)","Standard of Care","Ranibizumab"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05210803","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-12-20 to 2031-07-01","comparator":null,"confidence":"structured-source","population":"ALL","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.810Z","intervention":["Standard of Care","Ranibizumab"],"participants":116,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidences of ocular Adverse Events and any Serious Adverse Events — 5 years inclusive of parent study","Incidences of non-ocular Adverse Events and any Adverse Events of Special Interest — 5 years inclusive of parent study","Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA based on ETDRS score i…","Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CRT as measured by SD-OCT i…","Mean number of supplemental anti-VEGF injections through years 2, 3, 4 and 5 — 5 years inclusive of parent study","Mean number of supplemental anti-VEGF injections in years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean supplemental anti-VEGF injection annualized rate through years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean supplemental anti-VEGF injection annualized rate in years 2, 3, 4, and 5 — 5 years inclusive of parent study","Mean number of retina specialist visits attended for nAMD through years 2, 3, 4, and 5 — 5 years inclusive of parent st…","Mean number of retina specialist visits attended for nAMD in years 2, 3, 4, and 5 — 5 years inclusive of parent study"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41429","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}